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Abstract
GAW20 provided a platform for developing and evaluating statistical methods to analyze human lipid-related
phenotypes, DNA methylation, and single-nucleotide markers in a study involving a pharmaceutical intervention. In
this article, we present an overview of the data sets and the contributions analyzing these data. The data, donated
by the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) investigators, included data from 188 families
(N = 1105) which included genome-wide DNA methylation data before and after a 3-week treatment with fenofibrate,
single-nucleotide polymorphisms, metabolic syndrome components before and after treatment, and a variety of
covariates. The contributions from individual research groups were extensively discussed prior, during, and after the
Workshop in groups based on discussion themes, before being submitted for publication.
Background
This supplement to BMC Proceedings contains the pro-
ceedings of the GAW20 that was held March 4–8, 2017,
in San Diego, CA, USA. The GAWs were initiated in
1982 and have traditionally been held approximately
biannually. They provide a discussion forum for develop-
ing and evaluating statistical methods aimed at decipher-
ing the architecture of human complex diseases, mainly
by identifying their genetic risk factors. Discussion and
comparison of methods is facilitated by providing the
same data sets to all researchers. These data sets are
chosen by the GAW Advisory Committee, taking into
consideration the suggestions and concerns of attendees.
Discussion of future data sets begins the final day of the
Workshop and remains open for at least a year. Data
sets must be well characterized, address urgent needs for
analysis tools in genetic epidemiology, and be available
upon request prior to the Workshop. After the GAW or-
ganizers release the data sets, researchers analyze the
data and prepare a manuscript to submit to the Work-
shop. All coauthors of submitted manuscripts are eli-
gible to attend the Workshop. Active participation in
group discussions is required, as well as attendance at
overall presentation and discussion meetings. Individuals
who provided data or participate in the Workshop
organization may also attend. More information about
GAW, including upcoming Workshops, may be found at
http://www.gaworkshop.org.
Genetic analysis workshop 20
GAW20 was the first GAW to explore the emerging
field of epigenetic data, providing an opportunity to ex-
plore methodological questions of interest in epigenetics
in the context of a family-based, longitudinal study that
also included a pharmaceutical intervention. As with
previous GAWs, analyses of these data by GAW20 par-
ticipants largely focused on dealing with the high dimen-
sionality of the single-nucleotide polymorphism marker
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data, accounting for the family structure and handling
longitudinal data, with the new wrinkle of integrating
DNA methylation data, all within the context of a clinical
trial. These issues are natural considering the data set pro-
vided, which is described in detail in Aslibekyan et al. [1].
Although complete data set details are provided in
Aslibekyan et al. [1], we provide a brief overview of the
data set now as an introduction to this volume. Data from
188 families [N = 1105 individuals] participating in the
Genetics of Lipid Lowering Drugs and Diet Network
(GOLDN) study were the focus of analysis for GAW20.
Data available on these 1105 individuals consisted of: (a)
DNA methylation at 463,995 cytosine-phosphate-guanine
(CpG) sites measured before and after a 3-week treatment
with fenofibrate; (b) 906,000 single-nucleotide polymor-
phisms; (c) metabolic syndrome components ascertained
before and after the drug intervention; and (d) relevant co-
variates. Methylation and genotype data were subject to a
variety of standard filtering and quality control proce-
dures. GAW20 participants had the option of focusing
their methodological investigations on this “real” data or
on an alternative version that was simulated (“simulated
data”). Following a complex, but realistic, genetic model
that hypothesized genetic modification of methylation on
triglyceride levels at select loci, 200 replicates of simulated
posttreatment methylation and triglyceride measurements
were generated for each individual. Simulated data
provided participants the opportunity to provide
additional statistical validation and assessment of method
performance.
The availability of the GAW20 data was announced by
email in the fall of 2016 to roughly 3200 individuals on
the GAW mailing list, resulting in 81 separate requests
for data to participate in the Workshop. The number of
GAW20 attendees in March 2017 was 80. Although in-
dividuals were allowed to present more analyses at the
Workshop than had been described in their submitted
papers, each group was still required to report the re-
sults of some analyses prior to the meeting to partici-
pate. Manuscripts were distributed among participants
prior to the Workshop, and participants were assigned
to discussion groups to facilitate discussion before and
during the Workshop. Manuscripts from the other dis-
cussion groups were also available for download from
the GAW20 online discussion forum or upon request
prior to the Workshop. After the Workshop, 39 individ-
ual papers were accepted for publication and constitute
this proceedings volume, with 12 papers accepted for
publication in BMC Genetics.
Participants and contributions were from many coun-
tries, with the United States of America, Canada, and
Germany providing the largest numbers of contribu-
tions. Additional contributing participants were from
Australia, China, India, the United Kingdom, the
Netherlands, Norway, Poland, Spain and Taiwan. The
contributions were subdivided into 7 discussion groups
by topic, with 1 group split into 3 subgroups to facilitate
more detailed and focused discussions. The themes were
Causal Modeling (Group 1), Data Mining and Machine
Learning (Group 2), Epigenetics–Complex Models
(Group 3a), Epigenetics–Gene Searching (Group 3b),
Epigenetics–Longitudinal Analysis (Group 3c), GWAS
(Genome-wide Association Studies) (Group 4),
Genotype-by-Methylation (Group 5), Repeated Measures
(Group 6), and Genetics of Treatment Response (Group
7). The papers in this proceedings volume are presented
according to these groupings, with Groups 2 and 3a
merged because of the overlapping goals of the papers in
these groups. However, group assignment was often not
easy and topics in groups may overlap. The contributed
papers are preceded by the data description by
Aslibekyan et al. [1] and a description of the model used
to generate the simulated data by Kraja et al. [2]. Each
group was led by a moderator with previous GAW ex-
perience. The moderator encouraged and organized the
discussion and presentations prior to, during, and after
the Workshop. Discussions largely started before the
Workshop and continued at the Workshop within group
meetings. Each discussion group, directed by the group
leader, was also in charge of preparing a presentation of
the issues discussed in the group and the conclusions
drawn. These presentations were made to all GAW at-
tendees in plenary sessions. There were also 2 poster
sessions for presenting individual contributions. The
Workshop closed with plenary sessions on lessons
learned and planning for future GAWs. After the
Workshop, the group leader was typically in charge of
editing group manuscripts, as well as writing the sum-
mary paper for the group. To avoid possible conflicts of
interest, articles to which the group editor contributed
were reassigned to other groups for the editing process.
Summary papers and individual papers deemed to be of
highest impact are published in a supplement to BMC
Genetics, and all other individual contributions are
found in these proceedings.
Overall, GAW20 uncovered many new challenges and
unsolved problems with epigenetic and pharmacogenom-
ics data, although many of these challenges mirror those
identified in the analysis of GWAS and whole-genome
sequence data. The discussions highlighted the need
for methodological development in almost all consid-
ered areas.
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